This finding correlates with the known association of TP53 with poor outcomes in lung adenocarcinoma and unfavorable response to EGFR-TKIs39,40, and may have influenced the CANARY signature in the 5 EGFR mutant cases harboring concurrent TP53 mutations. Here, EGFR is linked to lung adenocarcinoma.